Background and Purpose: Reduced ambulatory activity is a major burden in neurodegenerative disease (NDD), leading to severe restrictions in social participation and further deterioration of motor capacities. However, objective evidence on walking behavior patterns and components underlying this impairment and its decline with disease progression is scarce for many NDDs. We aimed to unravel the detailed metrics underlying the reduced ambulatory activity in selected NDDs, and their relation to disease duration. We hypothesized that progressively reduced ambulatory activity is a feature shared across different NDDs, characterized by changes in both common and distinct components. Methods: Sixty-five subjects with NDD (n = 34 degenerative ataxia; n = 15 progressive supranuclear palsy, and n = 16 Parkinson's disease) and 38 healthy older adults (total n = 103) wore a three-axial accelerometer (activPAL3™) for 7 consecutive days. Detailed metrics of ambulatory activity were calculated. Results: The average daily walking duration was significantly decreased in all three NDDs, yet characterized by a differential pattern of changes in number and length of walking bouts and sit-to-stand transfers. Decline in walking duration progressed with increased disease duration in all three NDDs, yet at a differing rate. This decline was associated with progressive reductions in walking bout length and walking behavior pattern diversity in all three NDDs. Conclusions: These findings provide objective evidence that reduced ambulatory activity is a shared feature across different NDDs. Moreover, they reveal that several underlying walking behavior components change with increasing disease duration, yet at a differing rate in different NDDs. This indicates that metric analysis of ambulatory activity might provide ecologically relevant and disease-specific progression and outcome markers in several NDDs.

Keywords:
Ataxia, Parkinson’s disease, Progressive supranuclear palsy, Activity, Sensor, Accelerometer, Neurogeriatrics, Biomarker, Outcome parameter, Neurodegeneration
1.
Dorsey ER, George BP, Leff B, Willis AW: The coming crisis: obtaining care for the growing burden of neurodegenerative conditions. Neurology 2013;80:1989-1996.
2.
Fryer JD, Yu P, Kang H, et al: Exercise and genetic rescue of SCA1 via the transcriptional repressor Capicua. Science 2011;334:690-693.
3.
Speelman AD, van de Warrenburg BP, van Nimwegen M, Petzinger GM, Munneke M, Bloem BR: How might physical activity benefit patients with Parkinson disease? Nat Rev Neurol 2011;7:528-534.
4.
Safdar A, Bourgeois JM, Ogborn DI, et al: Endurance exercise rescues progeroid aging and induces systemic mitochondrial rejuvenation in mtDNA mutator mice. Proc Natl Acad Sci USA 2011;108:4135-4140.
5.
Warburton DE, Nicol CW, Bredin SS: Health benefits of physical activity: the evidence. CMAJ 2006;174:801-809.
6.
Van Nimwegen M, Speelman AD, Overeem S, et al: Promotion of physical activity and fitness in sedentary patients with Parkinson's disease: randomised controlled trial. BMJ 2013;346:f576.
7.
Maetzler W, Rochester L: Body-worn sensors - the brave new world of clinical measurement? Mov Disord 2015;30:1203-1205.
8.
Lord S, Godfrey A, Galna B, Mhiripiri D, Burn D, Rochester L: Ambulatory activity in incident Parkinson's: more than meets the eye? J Neurol 2013;260:2964-2972.
9.
De Lau LM, Breteler MM: Epidemiology of Parkinson's disease. Lancet Neurol 2006;5:525-535.
10.
Rochester L, Chastin SF, Lord S, Baker K, Burn DJ: Understanding the impact of deep brain stimulation on ambulatory activity in advanced Parkinson's disease. J Neurol 2012;259:1081-1086.
11.
Lim I, van Wegen E, Jones D, et al: Does cueing training improve physical activity in patients with Parkinson's disease? Neurorehabil Neural Repair 2010;24:469-477.
12.
Benka Wallen M, Franzen E, Nero H, Hagstromer M: Levels and patterns of physical activity and sedentary behavior in elderly people with mild to moderate Parkinson disease. Phys Ther 2015;95:1135-1141.
13.
Chastin SF, Baker K, Jones D, Burn D, Granat MH, Rochester L: The pattern of habitual sedentary behavior is different in advanced Parkinson's disease. Mov Disord 2010;25:2114-2120.
14.
Dontje ML, de Greef MH, Speelman AD, et al: Quantifying daily physical activity and determinants in sedentary patients with Parkinson's disease. Parkinsonism Relat Disord 2013;19:878-882.
15.
Litvan I, Agid Y, Calne D, et al: Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
16.
Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
17.
Klockgether T: Sporadic ataxia with adult onset: classification and diagnostic criteria. Lancet Neurol 2010;9:94-104.
18.
Van Gaalen J, van de Warrenburg BP: A practical approach to late-onset cerebellar ataxia: putting the disorder with lack of order into order. Pract Neurol 2012;12:14-24.
19.
Ryan CG, Grant PM, Tigbe WW, Granat MH: The validity and reliability of a novel activity monitor as a measure of walking. Br J Sports Med 2006;40:779-784.
20.
Grant PM, Ryan CG, Tigbe WW, Granat MH: The validation of a novel activity monitor in the measurement of posture and motion during everyday activities. Br J Sports Med 2006;40:992-997.
21.
Schwenk M, Hauer K, Zieschang T, Englert S, Mohler J, Najafi B: Sensor-derived physical activity parameters can predict future falls in people with dementia. Gerontology 2014;60:483-492.
22.
Kempen GI, Yardley L, van Haastregt JC, et al: The Short FES-I: a shortened version of the Falls Efficacy Scale-International to assess fear of falling. Age Ageing 2008;37:45-50.
23.
Nasreddine ZS, Phillips NA, Bedirian V, et al: The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
24.
Shumway-Cook A, Woollacott M: Motor Control Theory and Applications. Baltimore, Williams & Wilkins, 1995.
25.
Wenning GK, Tison F, Seppi K, et al: Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004;19:1391-1402.
26.
Schmitz-Hubsch T, du Montcel ST, Baliko L, et al: Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 2006;66:1717-1720.
27.
Goetz CG, Tilley BC, Shaftman SR, et al: Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
28.
Van der Kolk NM, van Nimwegen M, Speelman AD, et al: A personalized coaching program increases outdoor activities and physical fitness in sedentary Parkinson patients; a post-hoc analysis of the ParkFit trial. Parkinsonism Relat Disord 2014;20:1442-1444.
29.
Tudor-Locke C, Craig CL, Brown WJ, et al: How many steps/day are enough? For adults. Int J Behav Nutr Phys Act 2011;8:79.
30.
Maetzler W, Nieuwhof F, Hasmann SE, Bloem BR: Emerging therapies for gait disability and balance impairment: promises and pitfalls. Mov Disord 2013 28:1576-1586.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.